AIA Investment Management’s Moderna MRNA Stock Holding History

AIA Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$46K	Hold	653	–	–	0.01%	318
2020 Q2	$42K	Buy	+653	New	+$35.8K	0.01%	258

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIA Investment Management's MRNA Position: Q3 2020 in Review

AIA Investment Management held its Moderna (MRNA) position steady in Q3 2020 at 653 shares worth $46K. The position accounts for 0.01% of the portfolio, ranked #318.

AIA Investment Management first reported a position in MRNA in Q2 2020 and has held it in 2 quarters since. 547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

AIA Investment Management held 653 shares of Moderna worth $46K as of Q3 2020.
AIA Investment Management left its Moderna share count unchanged in Q3 2020.
Moderna made up 0.01% of AIA Investment Management's portfolio in Q3 2020, its #318 holding.
AIA Investment Management first reported a position in Moderna in Q2 2020 and has held it in 2 quarters since.
547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.